Abstract
Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporters, and is the first non-stimulant drug licensed for the treatment of attention-deficit hyperactivity disorder (ADHD).

This publication has 1 reference indexed in Scilit: